Newsstand | Page 9 | Aplastic Anemia & MDS International Foundation Return to top.


Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

FDA Grants Aspacytarabine Fast Track Status for Older Patients With AML

Originally Published: 08/04/2020
The FDA has granted a fast track designation for aspacytarabine as treatment for acute myeloid leukemia in adults aged 75 years or older who have comorbidities that preclude the utilization of intensive induction chemotherapy.   The FDA has granted a fast track designation for aspacytarabine (BST-236) as treatment for acute myeloid leukemia (AML) in adults aged 75 years or older who have comorbidities that preclude the utilization of intensive induction chemotherapy, according to an announcement from Biosight Ltd.1     “Receiving fast track designation from the FDA is an important...

Outrunning Cancer-Related Fatigue

Originally Published: 07/28/2020
When Honora Miller, 53, wondered how to explain her cancer-related fatigue to her son, a friend recommended using an analogy involving spoons. The spoon theory held that Miller would start each day with a certain number of the utensils, each one representing energy. Each daily activity cost a spoon. “Let’s say I only have 10 spoons today, but I do more than I should, in a sense borrowing from tomorrow’s spoons. I know that tomorrow will have to be a rest day because I won’t have enough spoons,” Miller says she told her son. “It has become a shorthand for us. My 14-year-old understands that...

What's New? Foundation Update Newsletter July 2020

Originally Published: 07/22/2020
There's something for everyone in the latest Foundation Update Newsletter! Patient & Family Conference Wrap-up | Thanks to Sponsors | Winners |Our Study was Published! | New Treatments | Webinars for August Read now at the link!

Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant

Originally Published: 07/06/2020
ABSTRACT While hematopoietic cell transplant from an HLA-matched unrelated donor is potentially curative for hematologic malignancy, survival is lower for African Americans compared to Caucasians. As only about 20% of African Americans will have an HLA-matched unrelated donor many of these patients undergo HLA-haploidentical relative or umbilical cord blood transplantation. Thus, the current analyses studied transplant-outcomes after HLA-haploidentical relative (n=249) and umbilical cord blood (n=118) transplants for African Americans with hematologic malignancy between 2008 and 2016. The...

Dealing with Stress and Anxiety as a Cancer Survivor

Originally Published: 06/30/2020
Disease recurrence is a common cause for the stress and anxiety typically experienced by cancer survivors even long after treatment ends. Several mental health experts provide some tips for easing these fears. June 2020 Vol 6 No 3 Adam Buffery A cancer diagnosis is an all-consuming and stressful event that drastically takes over a patient with cancer’s life. Patients with cancer may eventually get used to certain ways of doing things, including their treatment routine, and they may also get used to receiving the care and attention of their medical team and loved ones, said Karen L. Syrjala,...

What's New: Foundation Update Newsletter June 2020

Originally Published: 06/23/2020
What's inside:  National Patient & Family Conference | Celebrity Speakers | National March for Marrow | Clinical Trial | Medicine:  Clinic Practices for Bone Marrow Failure Patients | July Webinars | The Julia Malsin Research Fund Grant Announcement (please follow link for full news and information)

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Originally Published: 06/18/2020
Summary The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise...

Pevonedistat plus azacitidine may increase survival for myelodysplastic syndrome, AML

Originally Published: 06/15/2020
Pevonedistat plus azacitidine increased overall survival, event-free survival and response rates compared with azacytidine alone in higher-risk myelodysplastic syndromes and low-blast acute myeloid leukemia, according to data presented at ASCO. (continued at link)

Pegcetacoplan Outperforms Current Standard of Care in Paroxysmal Nocturnal Hemoglobinuria

Originally Published: 06/12/2020
The novel C3 inhibitor pegcetacoplan led to a significant improvement in hemoglobin level and other clinical outcomes at week 16 versus the current standard of care, eculizumab (Soliris) in patients with paroxysmal nocturnal hemoglobinuria (PNH), according to findings from the phase 3 PEGASUS trial, presented ahead of the 2020 European Hematology Association Annual Congress. (continued at link)

Ruxolitinib Improves Outcomes in aGVHD Across Subgroups

Originally Published: 06/12/2020
Ruxolitinib (Jakafi) induced a strong, durable response across several subgroups of patients with steroid-refractory acute graft-versus-host disease (aGVHD), according to data from the REACH2 trial presented at the 25th Annual European Hematology Congress. (continued at link)
Share with